Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the Nordic countries
Niklas Andersson, Emilia Myrup Thiesson, Ulrike Baum, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study
Freja Kirsebom, Nick Andrews, Julia Stowe, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 11, pp. 1235-1243
Open Access | Times Cited: 48
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case–control study
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 12, pp. 1089-1100
Open Access | Times Cited: 46
Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study
Celine Y. Tan, Calvin J. Chiew, Deanette Pang, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 12, pp. 1343-1348
Open Access | Times Cited: 34
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
Anne J. Huiberts, Brechje de Gier, Christina E. Hoeve, et al.
Eurosurveillance (2023) Vol. 28, Iss. 7
Open Access | Times Cited: 33
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
Angela R. Branche, Nadine Rouphael, David Diemert, et al.
Nature Medicine (2023) Vol. 29, Iss. 9, pp. 2334-2346
Open Access | Times Cited: 33
Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
Hagit Kopel, Văn Hùng Nguyễn, Cathérine Boileau, et al.
Vaccines (2023) Vol. 11, Iss. 11, pp. 1711-1711
Open Access | Times Cited: 22
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era
Shanti Pather, Alexander Muik, Ruben Rizzi, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 650-661
Open Access | Times Cited: 15
Immunogenicity of bivalent versus monovalent mRNA booster vaccination among adult paramedics in Canada who had received three prior mRNA wild-type doses
Michael Asamoah-Boaheng, David A. Goldfarb, Iryna Kayda, et al.
Access Microbiology (2025) Vol. 7, Iss. 1
Open Access
Optimizing vaccination campaign strategies considering societal characteristics
Serin Lee, Zelda B. Zabinsky, Shan Liu
Health Care Management Science (2025)
Closed Access
Bivalent booster effectiveness against severe COVID-19 outcomes in Finland, September 2022 – March 2023
Eero Poukka, Hanna Nohynek, Sirkka Goebeler, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 13
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial
Angela R. Branche, Nadine Rouphael, Cecilia Losada, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 4, pp. 560-564
Open Access | Times Cited: 12
Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults in the United States
Hagit Kopel, Văn Hùng Nguyễn, Cathérine Boileau, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 8
Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada
Ramandip Grewal, Sarah A. Buchan, Lena Nguyen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 7
Effectiveness of mRNA-1273 bivalent (Original and Omicron BA.4/BA.5) COVID-19 vaccine in preventing hospitalizations for COVID-19, medically attended SARS-CoV-2 infections, and hospital death in the United States
Hung Fu Tseng, Bradley K. Ackerson, Lina S. Sy, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 7
Relative vaccine effectiveness (rVE) of mRNA COVID-19 boosters in people aged at least 75 years in the UK vaccination programme, during the Spring-Summer (monovalent vaccine) and Autumn-Winter 2022 (bivalent vaccine) booster campaigns: a prospective test negative case-control study
Anastasia Chatzilena, Catherine Hyams, Robert Challen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
Responses to Common Misconceptions Relating to COVID-19 Variant-Adapted mRNA Vaccines
George Kassianos, Pauline MacDonald, Ivan Dinesh Aloysius, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 57-57
Open Access | Times Cited: 1
SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity
Simone I. Richardson, Nonkululeko Mzindle, Thopisang Motlou, et al.
Journal of Virology (2024) Vol. 98, Iss. 7
Closed Access | Times Cited: 1
Adapted vaccine strategy: facing the persistent challenges of COVID-19
Lianhan Shang, Bin Cao
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 9, pp. 984-985
Open Access | Times Cited: 4
Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023
Elina Seppälä, Jesper Dahl, Lamprini Veneti, et al.
Vaccine (2023) Vol. 42, Iss. 3, pp. 620-628
Open Access | Times Cited: 4
Long-term duration of protection of ancestral-strain monovalent vaccines and effectiveness of the bivalent BA.1 boosters against COVID-19 hospitalisation during a period of BA.5, BQ.1, CH.1.1. and XBB.1.5 circulation in England
Freja Kirsebom, Nick Andrews, Julia Stowe, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Why older adults can continue to benefit from covid-19 boosters
Kristine Macartney
BMJ (2023), pp. p1662-p1662
Open Access | Times Cited: 3
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection in the Netherlands, September to December 2022
Anne J. Huiberts, Brechje de Gier, Christina E. Hoeve, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations
Anna Stoliaroff-Pépin, Thomas Harder
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 8, pp. 881-882
Open Access | Times Cited: 2
Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: A review and case study
Sabir Meah, Xu Shi, Lars G. Fritsche, et al.
Science Advances (2023) Vol. 9, Iss. 51
Open Access | Times Cited: 2
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial
Angela R. Branche, Nadine Rouphael, Cecilia Losada, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top